Browse ENPP2

Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Note=Secreted by most body fluids including serum and CSF. Also by adipocytes and numerous cancer cells.
Domain PF01223 DNA/RNA non-specific endonuclease
PF01663 Type I phosphodiesterase / nucleotide pyrophosphatase
PF01033 Somatomedin B domain
Function

Hydrolyzes lysophospholipids to produce lysophosphatidic acid (LPA) in extracellular fluids. Major substrate is lysophosphatidylcholine. Also can act on sphingosylphosphphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility. Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP. Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation. Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein. May have a role in induction of parturition. Possible involvement in cell proliferation and adipose tissue development. Tumor cell motility-stimulating factor.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0006644 phospholipid metabolic process
GO:0006898 receptor-mediated endocytosis
GO:0009395 phospholipid catabolic process
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0016042 lipid catabolic process
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022604 regulation of cell morphogenesis
GO:0030335 positive regulation of cell migration
GO:0031346 positive regulation of cell projection organization
GO:0034638 phosphatidylcholine catabolic process
GO:0040017 positive regulation of locomotion
GO:0044242 cellular lipid catabolic process
GO:0045765 regulation of angiogenesis
GO:0046434 organophosphate catabolic process
GO:0046470 phosphatidylcholine metabolic process
GO:0048514 blood vessel morphogenesis
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0051272 positive regulation of cellular component movement
GO:0072673 lamellipodium morphogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0097164 ammonium ion metabolic process
GO:0097581 lamellipodium organization
GO:1901342 regulation of vasculature development
GO:1902743 regulation of lamellipodium organization
GO:1902745 positive regulation of lamellipodium organization
GO:2000147 positive regulation of cell motility
GO:2000392 regulation of lamellipodium morphogenesis
GO:2000394 positive regulation of lamellipodium morphogenesis
Molecular Function GO:0001871 pattern binding
GO:0004518 nuclease activity
GO:0004527 exonuclease activity
GO:0004528 phosphodiesterase I activity
GO:0004551 nucleotide diphosphatase activity
GO:0004620 phospholipase activity
GO:0004622 lysophospholipase activity
GO:0005044 scavenger receptor activity
GO:0008081 phosphoric diester hydrolase activity
GO:0008134 transcription factor binding
GO:0016298 lipase activity
GO:0030246 carbohydrate binding
GO:0030247 polysaccharide binding
GO:0038024 cargo receptor activity
GO:0042578 phosphoric ester hydrolase activity
GO:0047391 alkylglycerophosphoethanolamine phosphodiesterase activity
GO:0052689 carboxylic ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00565 Ether lipid metabolism
Reactome R-HSA-74160: Gene Expression
R-HSA-450520: HuR (ELAVL1) binds and stabilizes mRNA
R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-199220: Vitamin B5 (pantothenate) metabolism
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ENPP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ENPP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Sensitive to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ENPP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9410.173
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9590.637
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9390.584
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0160.965
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2260.89
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3210.874
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7910.152
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.590.752
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.010.629
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.120.941
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5440.813
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.040.81
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ENPP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475014.335.70.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENPP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENPP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENPP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENPP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ENPP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ENPP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolENPP2
Nameectonucleotide pyrophosphatase/phosphodiesterase 2
Aliases PD-IALPHA; autotaxin; PDNP2; ATX-X; LysoPLD; NPP2; E-NPP 2; autotaxin-t; extracellular lysophospholipase D; ......
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ENPP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.